Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L29 (RPL29) is a cytoplasmic ribosomal protein and a structural component of the 60S large ribosomal subunit in eukaryotic cells[1][6]. It is essential for proper ribosome biogenesis and global protein synthesis. In addition to its primary location in the ribosome, RPL29 is also expressed as a peripheral membrane protein on the cell surface, where it binds heparin and heparan sulfate, a property linked to modulation of angiogenesis and interaction with growth factors[1][2][5]. Functionally, RPL29 has roles in regulating cell proliferation, differentiation, and apoptosis—knockdown studies implicate it in cancer cell growth arrest and apoptosis, as well as the modulation of immune cell cytotoxicity[3]. Altered expression of RPL29 has been reported in various cancers and is associated with tumor cell behavior and tumorigenesis[3]. There are currently no approved drugs known to selectively target RPL29, and it is not a therapeutic target at this time; its essential role in ribosomal function makes it a potential risk for off-target effects if inhibited[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L29 (RPL29).